课题基金 / 基金详情

ACTG254--MICRONIZED ATOVAQUONE & AT/AZ AS COMPARED TO TM/ SMX

ACTG254--MICRONIZED ATOVAQUONE & AT/AZ AS COMPARED TO TM/ SMX
ACTG254--微粉化阿托伐醌
批准号:
6264756
负责人:
RICHARD RUTSTEIN
金额:
$0.06万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

RICHARD RUTSTEIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ACTG 254 is a comparative study of two drug combinations (atovaquone/azithromycin vs. trimethoprim/sulfamethoxazole) for the prevention of serious bacterial infections in HIV-infected children. The lower age limit for enrollment into this study was lowered to 3 months (from 2 years) in March 1997. On February 12, 1999, this study will close to accrual of patients older than 19 months of age. Treatment and data collection continue in all age cohorts. Preliminary data from a pharmacokinetic substudy suggest that there is no pharmacokinetic interaction between atovaquone and azithromycin. No preliminary efficacy data are available from this study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STUDY OF BMS-232632 IN COMBINATION REGIMENS IN ANTIRETROVIRAL THERAPY
  • 批准号:
    7207692
  • 项目类别:
  • 资助金额:
    $3.56万
  • 财政年份:
    2005
  • 负责人:
    RICHARD RUTSTEIN
  • 依托单位:
PACTG 326: ALVAC HIV VACCINES AND AIDSVAX B/B IN CHILDREN BORN TO HIV MOTHERS
  • 批准号:
    7207785
  • 项目类别:
  • 资助金额:
    $1.1万
  • 财政年份:
    2005
  • 负责人:
    RICHARD RUTSTEIN
  • 依托单位:
PACTG 326: ALVAC HIV VACCINES AND AIDSVAX B/B IN CHILDREN BORN TO HIV MOTHERS
  • 批准号:
    7041890
  • 项目类别:
  • 资助金额:
    $2.12万
  • 财政年份:
    2004
  • 负责人:
    RICHARD RUTSTEIN
  • 依托单位:
STUDY OF BMS-232632 IN COMBINATION REGIMENS IN ANTIRETROVIRAL THERAPY
  • 批准号:
    7041819
  • 项目类别:
  • 资助金额:
    $4.2万
  • 财政年份:
    2004
  • 负责人:
    RICHARD RUTSTEIN
  • 依托单位:
海外基金